News from neurovive pharmaceutical ab

Mar 22, 2013, 06:20 ET

600th Heart Attack Patient Recruited into Phase III CicloMulsion® CIRCUS Trial

NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European,...

Mar 18, 2013, 06:06 ET

NeuroVive Appoints Anna Malm Bernsten and Boel Flodgren to its Board of Directors

NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company announces that Anna Malm Bernsten and Boel Flodgren have been elected to the...

Mar 11, 2013, 05:35 ET

NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica

NeuroVive, a leading mitochondrial medicine company, announces it has completed the acquisition of a portfolio of novel cyclophilin inhibitors,...

Dec 03, 2012, 04:35 ET

NeuroVive Announces Publication of Phase I Clinical Trial of CicloMulsion® in Clinical Drug Investigation

NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion® in the scientific journal Clinical...

Apr 19, 2011, 07:00 ET

First Heart Attack Patient Treated in European Cardioprotection Phase III trial with NeuroVive's CicloMulsion(TM)

Investigator-initiated European multicenter trial of 1,000 acute heart attack patients will examine the ability of cyclosporine to protect...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer